157 related articles for article (PubMed ID: 16420067)
61. Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7,8-dihydropteridin-6(5H)-ones as potent and selective Hsp90 inhibitors.
Li X; Shocron E; Song A; Patel N; Sun CL
Bioorg Med Chem Lett; 2009 May; 19(10):2860-4. PubMed ID: 19395259
[TBL] [Abstract][Full Text] [Related]
62. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
Park H; Kim YJ; Hahn JS
Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
[TBL] [Abstract][Full Text] [Related]
63. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
64. 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer.
Chen Z; Venkatesan AM; Dehnhardt CM; Dos Santos O; Delos Santos E; Ayral-Kaloustian S; Chen L; Geng Y; Arndt KT; Lucas J; Chaudhary I; Mansour TS
Bioorg Med Chem Lett; 2009 Sep; 19(17):4980-3. PubMed ID: 19640711
[TBL] [Abstract][Full Text] [Related]
65. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
66. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
Davies NG; Browne H; Davis B; Drysdale MJ; Foloppe N; Geoffrey S; Gibbons B; Hart T; Hubbard R; Jensen MR; Mansell H; Massey A; Matassova N; Moore JD; Murray J; Pratt R; Ray S; Robertson A; Roughley SD; Schoepfer J; Scriven K; Simmonite H; Stokes S; Surgenor A; Webb P; Wood M; Wright L; Brough P
Bioorg Med Chem; 2012 Nov; 20(22):6770-89. PubMed ID: 23018093
[TBL] [Abstract][Full Text] [Related]
67. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
[TBL] [Abstract][Full Text] [Related]
68. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.
Terasaka T; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2005 Jul; 48(15):4750-3. PubMed ID: 16033254
[TBL] [Abstract][Full Text] [Related]
69. Boc-lysinated-betulonic acid: a potent, anti-prostate cancer agent.
Saxena BB; Zhu L; Hao M; Kisilis E; Katdare M; Oktem O; Bomshteyn A; Rathnam P
Bioorg Med Chem; 2006 Sep; 14(18):6349-58. PubMed ID: 16777417
[TBL] [Abstract][Full Text] [Related]
70. Design and semisynthesis of novel fredericamycin A derivatives with an improved antitumor profile.
Abel U; Simon W; Eckard P; Hansske FG
Bioorg Med Chem Lett; 2006 Jun; 16(12):3292-7. PubMed ID: 16621542
[TBL] [Abstract][Full Text] [Related]
71. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
[TBL] [Abstract][Full Text] [Related]
72. Targeting Hsp90 for the treatment of cancer.
Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
[TBL] [Abstract][Full Text] [Related]
73. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
74. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
75. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
Patel HJ; Patel PD; Ochiana SO; Yan P; Sun W; Patel MR; Shah SK; Tramentozzi E; Brooks J; Bolaender A; Shrestha L; Stephani R; Finotti P; Leifer C; Li Z; Gewirth DT; Taldone T; Chiosis G
J Med Chem; 2015 May; 58(9):3922-43. PubMed ID: 25901531
[TBL] [Abstract][Full Text] [Related]
76. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.
Wang C; Barluenga S; Koripelly GK; Fontaine JG; Chen R; Yu JC; Shen X; Chabala JC; Heck JV; Rubenstein A; Winssinger N
Bioorg Med Chem Lett; 2009 Jul; 19(14):3836-40. PubMed ID: 19410458
[TBL] [Abstract][Full Text] [Related]
77. Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors.
Vijay Kumar D; Hoarau C; Bursavich M; Slattum P; Gerrish D; Yager K; Saunders M; Shenderovich M; Roth BL; McKinnon R; Chan A; Cimbora DM; Bradford C; Reeves L; Patton S; Papac DI; Williams BL; Carlson RO
Bioorg Med Chem Lett; 2012 Jul; 22(13):4377-85. PubMed ID: 22632936
[TBL] [Abstract][Full Text] [Related]
78. Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
Ibrahim MA; Johnson HW; Jeong JW; Lewis GL; Shi X; Noguchi RT; Williams M; Leahy JW; Nuss JM; Woolfrey J; Banica M; Bentzien F; Chou YC; Gibson A; Heald N; Lamb P; Mattheakis L; Matthews D; Shipway A; Wu X; Zhang W; Zhou S; Shankar G
J Med Chem; 2012 Feb; 55(3):1368-81. PubMed ID: 22214363
[TBL] [Abstract][Full Text] [Related]
79. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
80. Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100.
Kim SH; Tangallapally R; Kim IC; Trovato R; Parker D; Patton JS; Reeves L; Bradford C; Wettstein D; Baichwal V; Papac D; Bajji A; Carlson R; Yager KM
Bioorg Med Chem Lett; 2015 Nov; 25(22):5254-7. PubMed ID: 26483201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
